PALB2 and familial pancreatic carcinoma: Moreover, a phase II study, conducted in 2020, analyzed outcomes of pancreatic cancer patients with BRCA1/2 or PALB2 mutations, treated with cisplatin-gemcitabine + veliparib and did demonstrate a favorable ORR (65%) with chemotherapy but not a clear benefit with the addition of PARPi (74% of ORR, 10.1 months of PFS vs. 9.7 months, 15.5 months of OS vs. 16.4 months) [43].